Interim Phase 2a results in study participants with hypertriglyceridaemia treated with a single dose of the quaternary Gal-NAc siRNA, RN0361, have shown dose-dependent, clinically meaningful, durable reductions in apoCIII and TG levels for up to six months.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
